Activation of the purine salvage pathway in mononuclear cells of cardiac recipients treated with mycophenolate mofetil

被引:15
作者
Devyatko, Elena
Zuckerman, Andreas
Bohdjalian, Arthur
Roedler, Suzanne
Dunkler, Daniela
Grimm, Michael
Weigel, Guenter
机构
[1] Med Univ Vienna, Surg Clin, Dept Gen Surg & Transplantat, A-1090 Vienna, Austria
[2] Univ Vienna, Surg Clin, Dept Cardiothorac Surg, Vienna, Austria
关键词
heart transplantation; immunosuppression; mycophenolate mofetil; mechanism of action;
D O I
10.1097/01.tp.0000225759.54343.23
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Background. The objective of this study was to investigate purine nucleotide metabolism in peripheral blood mononuclear cells (PBMC) of cardiac transplant recipients switched from azathioprine to mycophenolate mofetil (MMF). Methods. Concentrations of guanosine 5'triphosphate (GTP) and adenosine 5'triphosphate (ATP), the activities of inosine monophosphate dehydrogenase (IMPDH), guanine phosphoribosyltransferase (GPRT), and hypoxanthine phosphoribosyltransferase (HPRT) were determined in PBMC of 27 cardiac transplant recipients before switch to MMF and 3, 6, and 12 months thereafter. Results. There was no difference in the activities of IMPDH and salvage pathway enzymes GPRT and HRPT as well as in intracellular GTP and ATP concentrations between the patients before switch to MMF and healthy controls. The GTP and ATP concentrations in PBMC of cardiac recipients did not change during the entire observation period. Although the MPA trough level remained similar, IMPDH activity declined from 897 to 316 pmol/10(6)PBMC/h 3 months after MMF onset, was almost completely inhibited after 6 months, and partially restored to 143 pmol/10(6)PBMC/h 12 months after switch to MMF. In contrast, GPRT activity increased after 3, 6, and 12 months of MMF therapy and HPRT activity 3 and 6 months after switch to MMF. Conclusions. We demonstrated for the first time an induction of salvage pathway enzyme activities in PBMC under MMF therapy. This probably accounts for the maintenance of intracellular purine nucleotide pools and prevents the GTP depletion.
引用
收藏
页码:113 / 118
页数:6
相关论文
共 23 条
[1]
Mycophenolate mofetil and its mechanisms of action [J].
Allison, AC ;
Eugui, EM .
IMMUNOPHARMACOLOGY, 2000, 47 (2-3) :85-118
[2]
Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? [J].
Birkeland, SA ;
Hamilton-Dutoit, S .
TRANSPLANTATION, 2003, 76 (06) :984-988
[3]
STATISTICS NOTES .12. CALCULATING CORRELATION-COEFFICIENTS WITH REPEATED OBSERVATIONS .1. CORRELATION WITHIN-SUBJECTS [J].
BLAND, JM ;
ALTMAN, DG .
BRITISH MEDICAL JOURNAL, 1995, 310 (6977) :446-446
[4]
Pharmacodynamic monitoring of mycophenolate mofetil [J].
Budde, K ;
Glander, P ;
Bauer, S ;
Braun, K ;
Waiser, J ;
Fritsche, L ;
Mai, I ;
Roots, I ;
Neumayer, HH .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2000, 38 (11) :1213-1216
[5]
Mycophenolate mofetil for solid organ transplantation: Does the evidence support the need for clinical pharmacokinetic monitoring? [J].
Cox, VC ;
Ensom, MHH .
THERAPEUTIC DRUG MONITORING, 2003, 25 (02) :137-157
[6]
Influence of mycophenolic acid on inosine 5'-monophosphate dehydrogenase activity in human peripheral blood mononuclear cells [J].
Daxecker, H ;
Raab, M ;
Müller, MM .
CLINICA CHIMICA ACTA, 2002, 318 (1-2) :71-77
[7]
Value of mycophenolic acid trough level monitoring after lung transplantation [J].
Devyatko, E ;
Ploner, M ;
Zuckermann, A ;
Jaksch, P ;
Tschernko, E ;
Klepetko, W ;
Wisser, W .
TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) :1881-1883
[8]
Griesmacher A, 1997, CLIN CHEM, V43, P2312
[9]
Treatment by mycophenolate mofetil of advanced graft vascular disease in non-human primate recipients of orthotopic aortic allografts [J].
Klupp, J ;
Dambrin, C ;
Hibi, K ;
Luna, J ;
Suzuki, T ;
Hausen, B ;
Birsan, T ;
van Gelder, T ;
Fitzgerald, PJ ;
Berry, G ;
Morris, RE .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (07) :817-829
[10]
A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients [J].
Kobashigawa, J ;
Miller, L ;
Renlund, D ;
Mentzer, R ;
Alderman, E ;
Bourge, R ;
Costanzo, M ;
Eisen, H ;
Dureau, G ;
Ratkovec, R ;
Hummel, M ;
Ipe, D ;
Johnson, J ;
Keogh, A ;
Mamelok, R ;
Mancini, D ;
Smart, F ;
Valantine, H .
TRANSPLANTATION, 1998, 66 (04) :507-515